Ripal T Gandhi

Dr. Ripal T Gandhi

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2025 in Circulation
Verified
Journal Article
Open access
WJWissam A. Jaber
Wissam A. Jaber
CGCarin F. Gonsalves
Carin F. Gonsalves
SSStefan Stortecky
Stefan Stortecky
SHSamuel Horr
Samuel Horr
OPOrestis Pappas
Orestis Pappas
FIfor the PEERLESS Committees and Investigators*
for the PEERLESS Committees and Investigators*
BACKGROUND: There are a lack of randomized controlled trial data comparing outcomes of different catheter-based interventions for intermediate-risk pulmonary embolism. METHODS: PEERLESS is a prospective, multicenter, randomized controlled trial that enrolled 550 patients with intermediate-risk pulmonary embolism with right ventricular dilatation and additional clinical risk factors randomized 1:1 to treatment with large-bore mechanical thrombectomy (LBMT) or catheter-directed thrombolysis (CDT). The primary end point was a hierarchal win ratio composite of the following (assessed at the sooner of hospital discharge or 7 days after the procedure): (1) all-cause mortality, (2) intracranial hemorrhage, (3) major bleeding, (4) clinical deterioration and/or escalation to bailout, and (5) postprocedural intensive care unit admission and length of stay. Assessments at the 24-hour visit included respiratory rate, modified Medical Research Council dyspnea score, New York Heart Association classification, right ventricle/left ventricle ratio reduction, and right ventricular function. End points through 30 days included total hospital stay, all-cause readmission, and all-cause mortality. RESULTS: The primary end point occurred significantly less frequently with LBMT compared with CDT (win ratio, 5.01 [95% CI, 3.68–6.97]; P <0.001). There were significantly fewer episodes of clinical deterioration and/or bailout (1.8% versus 5.4%; P =0.04) with LBMT compared with CDT and less postprocedural intensive care unit use ( P 24 hours (19.3% versus 64.5%). There were no significant differences in mortality, intracranial hemorrhage, or major bleeding between strategies or in a secondary win ratio end point including the first 4 components (win ratio, 1.34 [95% CI, 0.78–2.35]; P =0.30). At the 24-hour visit, respiratory rate was lower for patients treated with LBMT (18.3±3.3 versus 20.1±5.1; P <0.001), and fewer had moderate to severe modified Medical Research Council dyspnea scores (13.5% versus 26.4%; P <0.001), New York Heart Association classifications (16.3% versus 27.4%; P =0.002), and right ventricular dysfunction (42.1% versus 57.9%; P =0.004). Right ventricle/left ventricle ratio reduction was similar (0.32±0.24 versus 0.30±0.26; P =0.55). Patients treated with LBMT had shorter total hospital stays (4.5±2.8 overnights versus 5.3±3.9 overnights; P =0.002) and fewer all-cause readmissions (3.2% versus 7.9%; P =0.03), whereas 30-day mortality was similar (0.4% versus 0.8%; P =0.62). CONCLUSIONS: PEERLESS met its primary end point in favor of LBMT compared with CDT in treatment of intermediate-risk pulmonary embolism. LBMT had lower rates of clinical deterioration and/or bailout and postprocedural intensive care unit use compared with CDT, with no difference in mortality or bleeding. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05111613.

3 May 2024 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
JGJay Giri
Jay Giri
FMFelix Mahfoud
Felix Mahfoud
BGBernhard Gebauer
Bernhard Gebauer
AAAsger Andersen
Asger Andersen
OFOren Friedman
Oren Friedman
FWFrances M. West
Frances M. West
Anticoagulation (AC) is the guideline-recommended treatment for intermediate-risk pulmonary embolism (PE); however, it remains unclear whether mechanical thrombectomy provides benefit over AC alone. The PEERLESS II study aims to evaluate outcomes in intermediate-risk PE patients randomized to treatment with large-bore mechanical thrombectomy and AC vs AC alone. PEERLESS II is an international randomized controlled trial enrolling up to 1200 patients with intermediate-risk PE and additional clinical risk factors from up to 100 sites. Treatment is randomized 1:1 to large-bore mechanical thrombectomy with the FlowTriever System (Inari Medical) and AC or AC alone. Outcomes will be evaluated for up to 3 months, with safety events independently adjudicated. The primary end point is a hierarchical composite win ratio of (1) all-cause mortality by 30 days, (2) clinical deterioration (earlier of discharge or 30 days), (3) all-cause hospital readmission by 30 days, (4) bailout therapy (earlier of discharge or 30 days), and (5) Modified Medical Research Council (mMRC) dyspnea score of ≥1 at the 48-hour visit. Secondary end points include all-cause and PE-related mortality (30-day and 90-day), all-cause and PE-related readmission (30-day and 90-day), major bleeding (30-day and 90-day), clinical deterioration (earlier of discharge or 30 days), bailout (earlier of discharge or 30 days), right ventricle-to-left ventricle diameter ratio (48-hour visit), mMRC dyspnea score (48-hour, 1-month, and 3-month visits), quality of life using Pulmonary Embolism Quality of Life and EuroQol-5 Dimensions-5 Levels (1-month and 3-month visits), 6-minute walk distance (1-month visit), and post-PE impairment diagnosis (3-month visit). PEERLESS II will inform the understanding of mechanical thrombectomy treatment for intermediate-risk PE and provide evidence for consideration in future treatment guidelines.

1 April 2018 in Cardiovascular Diagnosis and Therapy
Verified
Journal Article
Closed access
PDF file
YBYolanda Bryce
Yolanda Bryce
BSBrian Schiro
Brian Schiro
KCKyle Cooper
Kyle Cooper
SGSuvranu Ganguli
Suvranu Ganguli
MKMamdouh Khayat
Mamdouh Khayat
RGRipal T Gandhi
Ripal T Gandhi
Elective abdominal aortic aneurysm (AAA) repair is recommended for aneurysms greater than 5.5 cm, symptomatic, or rapidly expanding more than 0.5 cm in 6 months. Seventy-five percent of AAAs today are treated with endovascular aneurysm repair (EVAR) rather than open repair. This is fostered by the lower periprocedural mortality, complications, and length of hospital stay associated with EVAR. However, some studies have demonstrated EVAR to result in higher reintervention rates than with open repair, largely due to endoleaks. Type II is the most common, making up 10–25% of all endoleaks. Type II endoleaks, can potentially enlarge and pressurize the aneurysm sac with a risk of rupture. However, many type II endoleaks spontaneously resolve or never lead to sac enlargement. Imaging surveillance and approaches to management of type II endoleaks are reviewed here.

1 October 2022 in Radiology
Verified
Journal Article
Closed access
EEErica C. Emmons
Erica C. Emmons
SBSteven Bishay
Steven Bishay
LDLiping Du
Liping Du
HKHenry Krebs
Henry Krebs
RGRipal T Gandhi
Ripal T Gandhi
DBDaniel B. Brown
Daniel B. Brown
Transarterial radioembolization with yttrium 90 microspheres resulted in 15.0-month overall survival in 498 participants with metastatic colorectal cancer: 17.4 months when integrated with second-l... Background Patients with unresectable, chemorefractory hepatic metastases from colorectal cancer have considerable mortality. The role of transarterial radioembolization (TARE) with yttrium 90 (90Y...

9 December 2022 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
TRTaylor J. Robinson
Taylor J. Robinson
LDLiping Du
Liping Du
LMLea Matsuoka
Lea Matsuoka
DSDaniel Y. Sze
Daniel Y. Sze
AKAndrew S. Kennedy
Andrew S. Kennedy
DBDaniel B. Brown
Daniel B. Brown

1 September 2018 in Techniques in Vascular and Interventional Radiology
Verified
Journal Article
Closed access
YBYolanda Bryce
Yolanda Bryce
CLCuong (Ken) Lam
Cuong (Ken) Lam
SGSuvranu Ganguli
Suvranu Ganguli
BSBrian J. Schiro
Brian J. Schiro
KCKyle Cooper
Kyle Cooper
RGRipal T Gandhi
Ripal T Gandhi